Site Search

DEUTSCH All Languages

Companies in the News

Photocure ASA (OSL:PHO) Termination Of Market Maker Agreement

Photocure ASA (OSL:PHO) Oslo, Norway, 22 December 2008

Photocure ASA terminates the market maker agreement with DnB NOR Markets.

DnB NOR Markets will continue to act as market maker up to and including 28 February 2009.

For further information, contact:

President and CEO Kjetil Hestdal E-mail: kh@photocure.no Mobile: +47 913 19 535 Office: +47 22 06 22 10

CFO Christian Fekete E-mail: cf@photocure.no Mobile: +47 916 42 938 Office: +47 22 06 22 10

www.photocure.com

Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer.

Photocure has two proprietary pharmaceutical products on the market: Metvix®, for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix®, for the diagnosis of bladder cancer. In addition, the company has developed a proprietary light source, the Aktilite® lamp, which is used in combination with the Metvix cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products and technologies.

Photocure®, Metvix®, Hexvix® and Aktilite® are registered trademarks of Photocure ASA.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Photocure ASA

http://www.photocure.com

ISIN: NO0010000045

Stock Identifier: XOSL.PHO

Verbundene Unternehmen

B&B Tools AB

ABN Newswire Diese Seite wurde besucht: (letzten 7 Tagen: 5) (letzten 30 Tagen: 22) (seit Veröffentlichung: 939)